Regulation of mhc i molecules in glioblastoma cells and the sensitizing of nk cells

Timo Burster; Fabian Gärtner; Christiane Bulach; Anuar Zhanapiya; Adrian Gihring; Uwe Knippschild

doi:10.3390/ph14030236

Regulation of mhc i molecules in glioblastoma cells and the sensitizing of nk cells

Timo Burster
, Fabian Gärtner
, Christiane Bulach
, Anuar Zhanapiya
, Adrian Gihring
, Uwe Knippschild

Ulm University
Nazarbayev University

Research output: Contribution to journal › Review article › peer-review

37 Citations (SciVal)

Abstract

Immunotherapy has been established as an important area in the therapy of malignant diseases. Immunogenicity sufficient for immune recognition and subsequent elimination can be by-passed by tumors through altered and/or reduced expression levels of major histocompatibility complex class I (MHC I) molecules. Natural killer (NK) cells can eliminate tumor cells in a MHC I antigen presentation‐independent manner by an array of activating and inhibitory receptors, which are promising candidates for immunotherapy. Here we summarize the latest findings in recogniz-ing and regulating MHC I molecules that affect NK cell surveillance of glioblastoma cells.

Original language	English
Article number	236
Journal	Pharmaceuticals
Volume	14
Issue number	3
DOIs	https://doi.org/10.3390/ph14030236
Publication status	Published - Mar 2021

Funding

Funding: T.B. was funded by the Nazarbayev University Faculty‐Development Competitive Re‐ search Grants Program, reference: 280720FD1907.

Keywords

Cathepsin G
Immunotherapy
MHC
NK cells
Proteases

ASJC Scopus subject areas

Molecular Medicine
Pharmaceutical Science

Access to Document

10.3390/ph14030236

Cite this

@article{8d032be0e0aa4a449ab74ba819885d07,

title = "Regulation of mhc i molecules in glioblastoma cells and the sensitizing of nk cells",

abstract = "Immunotherapy has been established as an important area in the therapy of malignant diseases. Immunogenicity sufficient for immune recognition and subsequent elimination can be by-passed by tumors through altered and/or reduced expression levels of major histocompatibility complex class I (MHC I) molecules. Natural killer (NK) cells can eliminate tumor cells in a MHC I antigen presentation‐independent manner by an array of activating and inhibitory receptors, which are promising candidates for immunotherapy. Here we summarize the latest findings in recogniz-ing and regulating MHC I molecules that affect NK cell surveillance of glioblastoma cells.",

keywords = "Cathepsin G, Immunotherapy, MHC, NK cells, Proteases",

author = "Timo Burster and Fabian G{\"a}rtner and Christiane Bulach and Anuar Zhanapiya and Adrian Gihring and Uwe Knippschild",

note = "Funding Information: Funding: T.B. was funded by the Nazarbayev University Faculty‐Development Competitive Re‐ search Grants Program, reference: 280720FD1907. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = mar,

doi = "10.3390/ph14030236",

language = "English",

volume = "14",

journal = "Pharmaceuticals",

issn = "1424-8247",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

TY - JOUR

T1 - Regulation of mhc i molecules in glioblastoma cells and the sensitizing of nk cells

AU - Burster, Timo

AU - Gärtner, Fabian

AU - Bulach, Christiane

AU - Zhanapiya, Anuar

AU - Gihring, Adrian

AU - Knippschild, Uwe

N1 - Funding Information: Funding: T.B. was funded by the Nazarbayev University Faculty‐Development Competitive Re‐ search Grants Program, reference: 280720FD1907. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/3

Y1 - 2021/3

N2 - Immunotherapy has been established as an important area in the therapy of malignant diseases. Immunogenicity sufficient for immune recognition and subsequent elimination can be by-passed by tumors through altered and/or reduced expression levels of major histocompatibility complex class I (MHC I) molecules. Natural killer (NK) cells can eliminate tumor cells in a MHC I antigen presentation‐independent manner by an array of activating and inhibitory receptors, which are promising candidates for immunotherapy. Here we summarize the latest findings in recogniz-ing and regulating MHC I molecules that affect NK cell surveillance of glioblastoma cells.

AB - Immunotherapy has been established as an important area in the therapy of malignant diseases. Immunogenicity sufficient for immune recognition and subsequent elimination can be by-passed by tumors through altered and/or reduced expression levels of major histocompatibility complex class I (MHC I) molecules. Natural killer (NK) cells can eliminate tumor cells in a MHC I antigen presentation‐independent manner by an array of activating and inhibitory receptors, which are promising candidates for immunotherapy. Here we summarize the latest findings in recogniz-ing and regulating MHC I molecules that affect NK cell surveillance of glioblastoma cells.

KW - Cathepsin G

KW - Immunotherapy

KW - MHC

KW - NK cells

KW - Proteases

UR - https://www.scopus.com/pages/publications/85103060738

UR - https://www.scopus.com/pages/publications/85103060738#tab=citedBy

U2 - 10.3390/ph14030236

DO - 10.3390/ph14030236

M3 - Review article

AN - SCOPUS:85103060738

SN - 1424-8247

VL - 14

JO - Pharmaceuticals

JF - Pharmaceuticals

IS - 3

M1 - 236

ER -

Regulation of mhc i molecules in glioblastoma cells and the sensitizing of nk cells

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this